{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}],"title":"<12 months"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":">12 months"},{"measurements":[{"groupId":"OG000","value":"18"}],"title":"No further treatment"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"description":"Number of months from study drug initiation to starting another treatment","groups":[{"description":"Daratumumab, 16mg/kg body weight in 1000 mL for the first dose, followed by 500mL for subsequent doses, once weekly for two months, then every 2 weeks for four months, then once each month for up to 24 total cycles.\n\nDaratumumab: Daratumumab by IV infusion once weekly for two months, then every 2 weeks for four months, then once each month until progression, inability to tolerate, or 24 cycles completed.","id":"OG000","title":"Daratumumab"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Time to Next Treatment","type":"SECONDARY","unitOfMeasure":"Participants"}